An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
Sponsors and Collaborators
+49 (0)761 15242 ext 75
Michael Staehler, Dr. med, Ludwig-Maximilians-University Munich, Hospital Grosshadern
Next post in Renal Cell Carcinoma Clinical Trials
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.